The efficacy and safety of 1470 nm diode laser in the treatment of benign prostatic hyperplasia: a prospective, multicenter study.

PURPOSE: Benign prostatic hyperplasia (BPH) is common in elderly men, causing lower urinary tract symptoms (LUTSs). The 1470 nm diode laser, with high vaporization efficiency and good hemostasis, is increasingly used for BPH. This study sought to comprehensively evaluate the efficacy and safety of 1470 nm diode laser enucleation of the prostate (DiLEP) forBPH in a prospective, multicenter study.

METHODS

Conducted at two hospitals, BPH patients were randomized into two groups. Group A used a new 1470 nm diode laser device (Hefei Han's Kereida), and Group B utilized a conventional and widely validated 1470 nm laser system (Wuhan Qizhi). Prostate volume (PV), maximum flow rate (Qmax), post-void residual (PVR), International Prostate Symptom Score (IPSS), and Quality of Life (QoL) score were measured pre- and post-operatively. Perioperative indices and complications were also recorded.

RESULTS

143 patients (73 in Group A, 70 in Group B) completed follow-up. Baseline characteristics of two groups were comparable. Vital parameters remained within normal ranges following the surgical procedure. Both groups showed significant improvements in IPSS, QoL, Qmax, and PVR post-operatively, with no significant differences between groups. Complications occurred in 17 patients in Group A and 10 in Group B, all of which resolved spontaneously or were effectively managed with appropriate interventions.

CONCLUSION

1470 nm DiLEP is an effective and safe BPH treatment, relieving symptoms with few complications. The new device from Hefei Han's Kereida performed reliably. This laser offers a valuable alternative to BPH surgeries.